
    
      Phase I Objectives

        -  To determine the Maximum Tolerated Dose (MTD) of the combination of (DOXIL) and Abraxane
           in patients with Metastatic Breast Cancer (MBC).

        -  Determine the dose-limiting toxicity (DLT) of DOXIL and Abraxane.

      Phase II Objectives

      Primary Objective

        -  To determine the response rate of DOXIL and Abraxane in patients with MBC.

      Secondary Objectives

        -  To determine the time to disease progression in patients with MBC receiving DOXIL and
           Abraxane.

        -  To assess the tolerability of this regimen in women with MBC and assess toxicity profile
    
  